Functional aspects of the CD30 gene in Hodgkin's lymphoma and anaplastic large cell lymphoma

Desiree Ho, Alex Rea, Lawrence Abraham

Research output: Contribution to journalLiterature review

1 Citation (Scopus)


Lymphomas are neoplasms of the human immune system and can be divided into two categories, Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Anaplastic large cell lymphoma (ALCL) is a form of NHL that shares a common distinctive feature with Hodgkin’s lymphoma, the overexpression of cytokine receptor, CD30. However, the responses in HL and ALCL differ. Activation of CD30 via its ligand, CD153 or antibodies triggers various cellular responses ranging from apoptosis to cell proliferation in ALCL but no response in HL. To further understand the role of these processes in the pathology, downstream signalling events arising from CD30 stimulation have been investigated; however, little is known about regulatory mechanisms that result in the characteristically high levels of CD30 in HL and ALCL. Here we review the studies that have focused on characterisation of the CD30 promoter as well as several factors that contribute to the transcriptional regulation of CD30 in these lymphomas.
Original languageEnglish
Pages (from-to)89-101
JournalOncology Reviews
Issue number2
Publication statusPublished - Jun 2009

Fingerprint Dive into the research topics of 'Functional aspects of the CD30 gene in Hodgkin's lymphoma and anaplastic large cell lymphoma'. Together they form a unique fingerprint.

Cite this